| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 06/13/2002 | WO2002045729A1 Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant argania spinosa |
| 06/13/2002 | WO2002045728A1 Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa |
| 06/13/2002 | WO2002045722A1 Preparation for the treatment of surface open wounds |
| 06/13/2002 | WO2002045718A1 Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells |
| 06/13/2002 | WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination |
| 06/13/2002 | WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases |
| 06/13/2002 | WO2002045699A2 Transdermal therapeutic system comprising the active ingredient oxybutynin |
| 06/13/2002 | WO2002045652A2 Tyrosine kinase inhibitors |
| 06/13/2002 | WO2002028842A3 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist |
| 06/13/2002 | WO2002028359A3 Concordantly uv-photoprotecting and artificial tanning compositions |
| 06/13/2002 | WO2002026929A3 Kini-3 motor protein and methods for its use |
| 06/13/2002 | WO2002026218A3 Fatty acid analogues for the treatment of proliferative skin disorders |
| 06/13/2002 | WO2002018353A3 Oxazolidinone chemotherapeutic agents |
| 06/13/2002 | WO2002008222A3 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001083438A3 New gamma selective retinoids |
| 06/13/2002 | WO2001082899A3 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| 06/13/2002 | WO2001062237A3 Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 06/13/2002 | WO2001037819A3 Use of indirubine derivatives for making medicines |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072616 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 06/13/2002 | US20020072609 Process for preparing arylacetylaminothiazoles |
| 06/13/2002 | US20020072526 Orally active salts with tyrosine kinase activity |
| 06/13/2002 | US20020072523 For therapy of inflammatory and immune diseases |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 06/13/2002 | US20020072509 Methods for the treatment of a traumatic central nervous system injury |
| 06/13/2002 | US20020072499 Specifically an N-formyl-methionyl-leucyl ("f-Met-Leu") tri-or tetra-peptide; pathological fibrosis or those caused by trauma or surgery |
| 06/13/2002 | US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen |
| 06/13/2002 | US20020072491 Homology to members of the myosin light chain kinase subfamily |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020071878 Anti proliferative preparations |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer. |
| 06/13/2002 | US20020071816 Contain alph-hydroxytetronic acid or a derivative, and, in some cases, hydroquinone, an alpha -hydroxy acid such as glycolic acid, and a fatty acid ester of ascorbic acid such as ascorbyl palmitate. |
| 06/13/2002 | US20020071815 Antipsoriatic nail polish |
| 06/13/2002 | DE10059826A1 Kosmetische, pharmazeutische und dermatologische Mittel Cosmetic, pharmaceutical and dermatological compositions |
| 06/13/2002 | DE10059822A1 Saure kosmetische, pharmazeutische und dermatologische Mittel Acid cosmetic, pharmaceutical and dermatological compositions |
| 06/13/2002 | DE10059819A1 Tensidhaltige kosmetische, dermatologische und pharmazeutische Mittel Surfactant-containing cosmetic, dermatological and pharmaceutical agents |
| 06/13/2002 | CA2678490A1 Isolated placental perfusate and placental cells isolated therefrom |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2436508A1 Liquid composition comprising an alcohol |
| 06/13/2002 | CA2435467A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | CA2431861A1 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2431171A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| 06/13/2002 | CA2431166A1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2430989A1 Method of collecting placental stem cells |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2429258A1 Piperidine/piperazine-type inhibitors of p38 kinase |
| 06/13/2002 | CA2428097A1 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | CA2426988A1 Multicomponent compositions containing chitosan and methods of preparing same |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1213025A1 Cosmetic and/or dermopharmaceutical composition containing extracts obtained from the leaves of Argania spinosa |
| 06/12/2002 | EP1213024A1 Cosmetic and/or dermopharmaceutical composition containing native proteins of Argania spinosa |
| 06/12/2002 | EP1213022A1 Method for purification of "Laist" for the treatment of dermatological disorders |
| 06/12/2002 | EP1213007A2 Personal care formulations |
| 06/12/2002 | EP1212941A2 Modulating ramp activity |
| 06/12/2002 | EP1212616A2 Inhibitors of binding between proteins and macromolecular ligands |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212417A2 Interleukin-1-receptor associated kinase-3 (irak3) |
| 06/12/2002 | EP1212410A2 Dna encoding the human serine protease eos |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212364A1 MATERIALS AND METHODS FOR INHIBITION OF IgE PRODUCTION |
| 06/12/2002 | EP1212362A2 Card proteins involved in cell death regulation |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212330A1 Androgen receptor modulator compounds and methods |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212323A2 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 06/12/2002 | EP1212322A2 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/12/2002 | EP1212317A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 06/12/2002 | EP1212303A2 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 06/12/2002 | EP1212302A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 06/12/2002 | EP1212299A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 06/12/2002 | EP1212100A2 Delivery system for antidandruff agent |
| 06/12/2002 | EP1212098A2 Enzyme inhibitors |
| 06/12/2002 | EP1212097A2 Enzyme inhibitors |
| 06/12/2002 | EP1212079A1 Topical treatment of streptococcal infections |
| 06/12/2002 | EP1212077A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 06/12/2002 | EP1212067A1 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 06/12/2002 | EP1212063A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 06/12/2002 | EP1212046A2 Flushable disposable polymeric products |
| 06/12/2002 | EP1212034A1 Enzyme inhibitors |
| 06/12/2002 | EP1211942A1 Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution |
| 06/12/2002 | EP1128844A4 Methods for enhancing wound healing |